Repligen Corp/ US7599161095 /
2024-03-28 9:00:00 PM | Chg. -0.8300 | Volume | Bid9:30:12 PM | Ask9:30:12 PM | High | Low |
---|---|---|---|---|---|---|
183.9200USD | -0.45% | 337,956 Turnover: 34.03 mill. |
83.9300Bid Size: 100 | 225.0000Ask Size: 100 | 187.2500 | 182.5600 |
GlobeNewswire
2023-12-19
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-07
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convert...
GlobeNewswire
2023-11-14
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
GlobeNewswire
2023-11-02
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
GlobeNewswire
2023-10-31
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
GlobeNewswire
2023-10-02
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire
2023-09-26
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
GlobeNewswire
2023-08-17
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Ups...
GlobeNewswire
2022-03-18
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
GlobeNewswire
2022-02-11
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
GlobeNewswire
2021-12-30
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference